Patents by Inventor Gerhard Bodo

Gerhard Bodo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5837842
    Abstract: This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: November 17, 1998
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Ingrid Maurer-Fogy, Gerhard Bodo, Peter Swetly, Christian Stratowa, Edgar Falkner, Gunther Adolf, Christiaan Maria Peter Reutelingsperger
  • Patent number: 5710027
    Abstract: Methods and vectors for expressing interferon-alpha (IFN-.alpha.) proteins in E. coli are provided. Use of a vector comprising an IFN-.alpha. sequence fused to an E. coli heat-stable enterotoxin signal sequence (STII) under the control of the E. coli phosphatase (phoA) promoter affords high levels of correctly-folded and -processed, biologically active IFN-.alpha. polypeptides.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: January 20, 1998
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Edgar Falkner, Gerhard Bodo, Tilman Voss, Ingrid Maurer-Fogy
  • Patent number: 5258497
    Abstract: The present invention relates to processes for purifying annexines. The overall process includes the steps of preparing a homogenized cell preparation and adjusting the pH to about 8.0 to 10.0, adding at least one bivalent cation, adding a phospholipid, washing the insoluble cell residue to remove the soluble constituents, and extracting the annexines from the cell residue with a chelating agent. This process initially promotes the adsorption of the annexines onto the insoluble cell residue or membrane of the host organism. The adsorption step makes it possible to eliminate unwanted soluble matter from the homogenized material by simple washing. Desorption is accomplished by using a chelating agent.
    Type: Grant
    Filed: July 13, 1990
    Date of Patent: November 2, 1993
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christiaan Reutelingsperger, Gerhard Bodo
  • Patent number: 5196323
    Abstract: A process for the preparation and purification of recombinant Interferon-.alpha. is disclosed. The invention is directed to a process comprising the following steps: cultivating E. coli containing the interferon gene for a growth period during which not more than 5% methionine-interferon is formed; extracting and concentrating the expressed interferon; subjecting the preliminarily purified material to Tandem Chromatography, wherein the Tandem Chromatography comprises separation on a cellulose column followed by an anti-alpha-interferon monoclonal antibody affinity column; subjecting the thus purified material to isoelectric precipitation of impurities at about pH 4.0 to about pH 4.8; and purifying the interferon by chromatography on a high performance cation exchange column using a volatile buffer, wherein the purified interferon is non-immunogenic when administered parenterally to a human.
    Type: Grant
    Filed: June 12, 1991
    Date of Patent: March 23, 1993
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerhard Bodo, Ingrid Maurer-Fogy, Edgar Falkner, Silvia J. Lindner
  • Patent number: 4917887
    Abstract: This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,new monoclonal antibodies and their use in purifying .alpha. and omega-interferons, the hybrid cell lines which secrete them and processes for preparing them,a new process for purifying .alpha. and omega-interferons by means of a new antibody affinity column containing the above-mentioned new monoclonal antibodies, and processes for the preparation thereof,new hybrid plasmids for improving the expression of omega-interferons and new intermediate plasmids for preparing the new plasmids and processes for the preparation thereof.
    Type: Grant
    Filed: March 9, 1987
    Date of Patent: April 17, 1990
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Peter Swetly, Peter Meindl, Gunther Adolf, Edgar Falkner, Gerhard Bodo, Ingrid Maurer-Fogy
  • Patent number: 4266024
    Abstract: This invention is directed to a process of producing interferon which comprises incubating permanent cell lines of lymphoblast origin or human fibroblast cells with interferon inducers and stimulator substances and recovering the interferon produced.
    Type: Grant
    Filed: May 14, 1979
    Date of Patent: May 5, 1981
    Assignee: Boehringer Ingelheim GmbH
    Inventors: Peter Swetly, Gunther R. Adolf, Gerhard Bodo, Silvia J. Lindner-Frimmel, Peter Meindl, Hans Tuppy
  • Patent number: 4021551
    Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl,R.sub.2 and R.sub.3, together with each other and the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring system which may optionally contain one or more additional heteroatoms, andA is lower alkylene or aryl-lower alkylene, and nontoxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as inducers of the formation of interferon.
    Type: Grant
    Filed: July 30, 1975
    Date of Patent: May 3, 1977
    Assignee: Boehringer Ingelheim GmbH
    Inventors: Ernest Cullen, Peter Meindl, Hans Tuppy, Gerhard Bodo